What Researchers Did
The researchers conducted a randomized trial to compare a portable hyperbaric chamber and dexamethasone for treating acute mountain sickness in 31 climbers at high altitude.
What They Found
After one hour of treatment, the hyperbaric chamber (193 mbar for 1 hour, simulating a 2250m descent) significantly reduced acute mountain sickness symptoms more than dexamethasone (e.g., Lake Louise score improved by -4.6 vs -2.5). However, about 11 hours later, subjects treated with dexamethasone had significantly less severe symptoms than those treated with the hyperbaric chamber (e.g., Lake Louise score improved by -7.0 vs -1.6). This suggests the hyperbaric chamber offered short-term relief, while dexamethasone provided more lasting benefits.
What This Means for Canadian Patients
For Canadian patients experiencing acute mountain sickness, this study suggests that a portable hyperbaric chamber can provide rapid, short-term relief from symptoms. However, for more sustained improvement over several hours, dexamethasone appears to be more effective. Patients and healthcare providers should consider these timeframes when choosing a treatment strategy for acute mountain sickness.
Canadian Relevance
Acute mountain sickness is not a Health Canada-recognized indication for hyperbaric oxygen therapy. No direct Canadian connection identified.
Study Limitations
The study involved a small number of participants (31 climbers) and only evaluated outcomes up to 11 hours post-treatment, limiting the generalizability and long-term understanding of the treatments.